Business Context and Reporting Period
This Form 8-K was filed by Aadi Bioscience, Inc. (trading symbol: AADI) on April 1, 2024. The report details a material definitive agreement entered into on the same date, effective as of March 31, 2024.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the terms of a contractual amendment rather than financial performance data.
Material Changes
The primary material change is the execution of Amendment No. 2 to the Negotiated Purchase Order Terms and Conditions for Clinical and Commercial Product with Fresenius Kabi, LLC. Key updates include:
- Extension of the agreement term until July 31, 2024, subject to mutual agreement for further extension.
- Revisions to pricing terms.
- Updates to forecasting requirements.
- Changes to compliance obligations.
- Revised obligations regarding the minimum quantities of FYARRO® the Company must purchase from Fresenius Kabi.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on financial outlook, or specific risk factors beyond the standard reference to the biotechnology industry context. The summary of the amendment is qualified by reference to the full text of the Amendment, which is to be filed as an exhibit in a subsequent periodic report.
Investor Verification Checklist
- Verify the specific revised pricing terms and minimum purchase quantities for FYARRO® in the full Amendment text.
- Confirm the exact end date of the agreement, noting the possibility of extension beyond July 31, 2024.
- Review the subsequent periodic report for the full exhibit of Amendment No. 2 to understand all customary terms applicable to the manufacture of therapeutics.